Ask AI

Practical Implementation of Newer Agents in HIV Treatment: Insights From the NCCC

Video
This activity is available for 0.50 CME/CE credit(s).

Released: October 20, 2026

Expiration: October 19, 2027

See Activity Collection

With numerous new and emerging regimens for HIV treatment, treatment goals are shifting to prioritize regimen optimization alongside maintenance of virologic suppression. Use this case-based video module to gain confidence navigating common ART optimization scenarios, including ART switch with little or no drug resistance or with complex drug resistance.

New Agents in HIV Treatment

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people living with HIV do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

What would you recommend for a person with virally suppressed HIV who wants to switch from their current complex regimen to an oral 2-drug regimen?

4.

What would you recommend for a person living with virally suppressed HIV who wants to switch from their current complex regimen to an oral 2-drug regimen, but who has an historical NRTI M184V mutation?

5.

I feel confident that I can select ART switches for virologically suppressed people who may benefit from simplification or optimization, including novel regimen options.